Home/Filings/4/0001209191-18-016866
4//SEC Filing

Herberts Curt A. III 4

Accession 0001209191-18-016866

CIK 0001001233other

Filed

Mar 4, 7:00 PM ET

Accepted

Mar 5, 6:39 PM ET

Size

22.1 KB

Accession

0001209191-18-016866

Insider Transaction Report

Form 4
Period: 2018-03-01
Herberts Curt A. III
Senior VP & CBO
Transactions
  • Exercise/Conversion

    Common Stock

    2018-03-01$14.07/sh+8,087$113,78424,313 total
  • Sale

    Common Stock

    2018-03-01$23.06/sh15,000$345,86114,625 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2018-03-018,08711,913 total
    Exercise: $14.07Exp: 2024-12-10Common Stock (8,087 underlying)
  • Exercise/Conversion

    Common Stock

    2018-03-01$12.12/sh+171$2,07314,796 total
  • Exercise/Conversion

    Common Stock

    2018-03-01$9.41/sh+1,430$13,45616,226 total
  • Exercise/Conversion

    Common Stock

    2018-03-01$3.50/sh+5,312$18,59229,625 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2018-03-011710 total
    Exercise: $12.12Exp: 2023-12-11Common Stock (171 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2018-03-011,43017,320 total
    Exercise: $9.41Exp: 2025-12-07Common Stock (1,430 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2018-03-015,31254,688 total
    Exercise: $3.50Exp: 2027-01-25Common Stock (5,312 underlying)
Footnotes (7)
  • [F1]All sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2017.
  • [F2]The price reported is a weighted average price. The shares were sold at prices ranging from $22.60 to $23.60 The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F3]Includes (a) 8,375 shares subject to restricted stock units granted on January 24, 2018 that will vest in three (3) equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date; and (b) 6,250 shares subject to restricted stock units granted on December 8, 2015 that will vest on December 8, 2018, subject to the Reporting Person's continued service with the Issuer through such date.
  • [F4]Fully vested and exercisable.
  • [F5]One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the December 11, 2014 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
  • [F6]One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the December 8, 2015 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.
  • [F7]The stock option vested and became exercisable for 25% of the shares upon the Reporting Person's completion of one year of service measured from the January 26, 2017 grant date, and the balance of the shares will vest and become exercisable in 36 successive equal monthly installments upon his completion of each additional month of service thereafter.

Issuer

SANGAMO THERAPEUTICS, INC

CIK 0001001233

Entity typeother

Related Parties

1
  • filerCIK 0001691262

Filing Metadata

Form type
4
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 6:39 PM ET
Size
22.1 KB